- Bharat Biotech, which is working on nasal vaccine CoroFlu against coronavirus in collaboration with US researchers, is also leading a CSIR-sanctioned project to develop human monoclonal antibodies as therapy for Covid-19 infection.
- The project aims at an alternative therapeutic regimen by generating specific human monoclonal antibodies that are capable of neutralising SARS-CoV2 virus. Such antibodies can block the spread of infection by binding to the virus and rendering it ineffective.
- Although different vaccines against Covid-19 are being developed across the world, their commercial production is bound to take a long time. Therefore, an alternative therapeutic regimen for early treatment is critical.